Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Update

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 3,380,000 shares, an increase of 7,076.2% from the June 30th total of 47,100 shares. Based on an average daily trading volume, of 12,230,000 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Kazia Therapeutics in a research report on Friday, July 12th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Platinum Investment Management Ltd. purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned about 11.15% of Kazia Therapeutics as of its most recent SEC filing. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Stock Performance

Shares of KZIA opened at $0.42 on Friday. The company’s fifty day moving average is $0.33 and its 200-day moving average is $0.32. Kazia Therapeutics has a 12 month low of $0.19 and a 12 month high of $1.58.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.